Christos Mantzoros, MD, DSc, PhD
Adjunct Professor
Boston University School of Medicine
Dept of Medicine
General Internal Medicine

MD, University of Athens
MMS/MMSc, Harvard Medical School
MSc, Harvard School of Public Health
DSc, University of Athens




Christos S. Mantzoros, MD, DSc, PhD h.c. mult., is a Professor of Medicine at Harvard Medical School and an Adjunct Professor at Boston University School of Medicine. He has also served as a Professor of Environmental Health at the Harvard School of Public Health. He currently serves as the Chief of Endocrinology, Diabetes and Metabolism at the Boston VA Healthcare System and the Director of the Human Nutrition Unit of the Division of Endocrinology Diabetes and Metabolism at Beth Israel Deaconess Medical Center. Dr. Mantzoros has been the editor of two books (one on “Diabetes and Obesity” and one on “Nutrition and Metabolism” with more than two editions each). His research has resulted in more than 800 publications in Medline, including more than 150 publications under the collaborative Look Ahead Research Group, more than 200 chapters and reviews, with more than 72,000 citations with a Hirsch Index H=121. Dr. Mantzoros is also the director for the VA Boston Healthcare System fellowship program with Boston University Medical Center (BUMC), which offers one dedicated fellowship position through BUMC, but also allows any fellow at BUMC or Harvard affiliated fellowship programs the opportunity to rotate through the VA Boston Healthcare System. He has served as a Board Member or an advisor or head of the Scientific Advisor Board of non for profit foundations as well as governmental and non-governmental entities. He is the Editor-in-Chief of the journal Metabolism and is on the editorial board of several scientific journals worldwide. For his research discoveries and public health service Dr. Mantzoros has received four honorary PhDs, the Alexander Technological Institute of Thessaloniki has named their nutrition laboratories after his name and several Universities worldwide have awarded Dr. Mantzoros honorary Professorships and visiting Professorships. He has or is supervising PhD thesis work in several nations worldwide (Sweden, Germany, Greece, USA etc) and is actively collaborating with many research groups worldwide. He has mentored more than 160 young scientists who currently hold key positions in clinical medicine, academia, industry as well as governmental agencies and nongovernmental organizations. Dr. Mantzoros has been elected a member of ASCI and a Fellow of the American College of Physicians and the American Association of Clinical Endocrinology. He has been given several awards including but not limited to awards by: the American Association of Clinical Endocrinology (Frontiers in Science Award), the American Diabetes Association (Novartis Award in Diabetes and Metabolic Diseases), the North American Association for the Study of Obesity / the Obesity Society (Lilly Award), the American Society for Nutrition (Mead Johnson Award), the HypoCCS award in Paris, France, the Humboldt Foundation of Germany (the Wilhelm Friedrich Bessel Award), by the American Federation of Medical Research (the Outstanding Investigator Award), by the American Physiological Society (FASEB, the Berson Award Lecture), by the New England Hellenic Medical and Dental Association (Hygeia award) etc. He has also received the BIDMC, Harvard Medical School, award for excellence in Mentoring. He will be receiving the 2018 European Society of Endocrinology Geoffrey Harris Prize.

Professor
Harvard Medical School
Medicine


Director
Beth Israel Deaconess Medical Center
Endocrinology, Diabetes, and Metabolism
Human Nutrition Unit

VA Boston Healthcare System
Endocrinology






Title
Lorcaserin in Obesity: Identification of CNS Targets Using fMRI


Yr Title Project-Sub Proj Pubs
2020 Adipokine physiology 5K24DK081913-10 96
2019 Adipokine physiology 5K24DK081913-09 96
2018 Adipokine physiology 5K24DK081913-08 96
2017 Adipokine physiology 5K24DK081913-07 96
2016 Adipokine physiology 2K24DK081913-06A1 96
2014 Leptin Signaling in Humans 5I01CX000422-04 19
2013 Leptin Signaling in Humans 5I01CX000422-03 19
2012 Leptin Signaling in Humans 5I01CX000422-02 19
2012 Leptin and Adipokine Physiology 5K24DK081913-05 96
2012 The Role of Leptin in the Maintenance of a Reduced Body Weight 5R01DK079929-05 67
Showing 10 of 61 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Deng Y, Lu L, Aponte L, Angelidi AM, Novak V, Karniadakis GE, Mantzoros CS. Deep transfer learning and data augmentation improve glucose levels prediction in type 2 diabetes patients. NPJ Digit Med. 2021 Jul 14; 4(1):109. PMID: 34262114; PMCID: PMC8280162; DOI: 10.1038/s41746-021-00480-x;
     
  2. Perakakis N, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. Int J Mol Sci. 2021 Jun 13; 22(12). PMID: 34199317; PMCID: PMC8232001; DOI: 10.3390/ijms22126332;
     
  3. Joung KE, Rifas-Shiman SL, Oken E, Mantzoros CS. Maternal Mid-pregnancy Leptin and Adiponectin Levels as Predictors of Autism Spectrum Disorder: A Prenatal Cohort Study. J Clin Endocrinol Metab. 2021 May 29. PMID: 34050756
     
  4. Tessier CM, Polyzos SA, Athyros VG, Mantzoros CS. Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe? Metabolism. 2021 Aug; 121:154796. PMID: 33989632
     
  5. Boutari C, Polyzos SA, Mantzoros CS. Addressing the epidemic of fatty liver disease: A call to action, a call to collaboration, a call to moving the field forward. Metabolism. 2021 Apr 24; 154781. PMID: 33901501
     
  6. Panagiotou G, Ghaly W, Upadhyay J, Pazaitou-Panayiotou K, Mantzoros CS. Serum Follistatin Is Increased in Thyroid Cancer and Is Associated With Adverse Tumor Characteristics in Humans. J Clin Endocrinol Metab. 2021 Apr 23; 106(5):e2137-e2150. PMID: 33493282
     
  7. Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis. Liver Int. 2021 Aug; 41(8):1853-1866. PMID: 33788377
     
  8. Muzurovic E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021 06; 119:154770. PMID: 33864798
     
  9. Tessier CM, Kokkinos A, Mingrone G, Koliaki C, Zierath JR, Mantzoros CS. COVID-19 editorial: mechanistic links and therapeutic challenges for metabolic diseases one year into the COVID-19 pandemic. Metabolism. 2021 06; 119:154769. PMID: 33775648; PMCID: PMC7997260; DOI: 10.1016/j.metabol.2021.154769;
     
  10. Vallianou NG, Stratigou T, Geladari E, Tessier CM, Mantzoros CS, Dalamaga M. Diabetes type 1: Can it be treated as an autoimmune disorder? Rev Endocr Metab Disord. 2021 Mar 17. PMID: 33730229
     
Showing 10 of 598 results. Show More